Biopharmaceutical major Biocon has launched a new injectable drug for treatment of breast cancer. Moreover, the company has priced it at Rs 57,500 (for a 440 mg vial), 25% lower than existing drugs. Notably, breast cancer is the second most common form of cancer among Indian women, with 1.5 lakh new patients being diagnosed with the disease every year. 